Physician profile
Parminder Singh
NPI 1194961763
$35,982.39
in general payments reported to CMS, 2019-2025
27 companies · $7,220 in 2025
The $7,220 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,742 · 2020: $5,217 · 2021: $4,991 · 2022: $2,440 · 2023: $4,943 · 2024: $1,430 · 2025: $7,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,113 · Food and Beverage: $2,879 · Travel and Lodging: $1,223 · Honoraria: $360 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,112.60 |
| Food and Beverage | $2,879.18 |
| Travel and Lodging | $1,222.62 |
| Honoraria | $360.00 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $5,149.97 | 2019-2022 | |
| Genentech USA, INC. | $4,491.17 | 2019-2025 | |
| Janssen Biotech, INC. | $4,463.18 | 2019 | |
| Seagen INC. | $4,376.63 | 2019-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $2,941.87 | 2020 | |
| Emd Serono, INC. | $2,805.00 | 2021 | |
| Aveo Pharmaceuticals, INC. | $2,703.32 | 2021-2025 | Fotivda |
| Astellas Pharma US INC | $2,200.00 | 2025 | Padcev |
| Exelixis INC. | $2,144.90 | 2023-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $2,014.40 | 2022 | |
| Gilead Sciences, INC. | $1,128.12 | 2021-2024 | Trodelvy |
| Daiichi Sankyo INC. | $360.00 | 2023 | |
| Tempus Ai, INC | $208.77 | 2025 | Xt Cdx |
| Abbott Laboratories | $208.47 | 2021-2022 | |
| Telix Pharmaceuticals | $145.54 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $139.50 | 2025 | Senza |
| Amgen INC. | $117.93 | 2022 | |
| Amarin Pharma, INC. | $97.03 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.57 | 2019-2021 | |
| Abiomed | $53.95 | 2025 | |
| Sumitomo Pharma America, INC. | $50.00 | 2025 | Orgovyx |
| Pfizer INC. | $33.81 | 2023-2024 | |
| Esperion Therapeutics, INC. | $24.86 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $19.90 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $18.13 | 2019 | |
| Avanos Medical | $14.37 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parminder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.